Evidence map›Paper›PMID 41815035›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

Disc-Toroid Hybrid Lipid Nanoparticles for Efficient Drug Encapsulation and Subcutaneous Delivery.

Zanelle van Niekerk, Rima Nuwayhid, Stefaniya Gaydarova, Eva Bittrich, Natalia Makarova, Susanne Boye, Christo Tzachev, Jan C Simon, Sandra Franz, Albena Lederer

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zanelle van NiekerkDepartment of Chemistry and Polymer Science, Stellenbosch University, Matieland, South Africa.
Rima NuwayhidClinic for Orthopaedics, Trauma Surgery and Plastic Surgery, Leipzig University Hospital, Leipzig, Germany.
Stefaniya GaydarovaFaculty of Chemistry and Pharmacy, Sofia University "St. Kliment Ohridski", Sofia, Bulgaria.
Eva BittrichLeibniz-Institut für Polymerforschung Dresden e.V., Dresden, Germany.
Natalia MakarovaLeibniz-Institut für Polymerforschung Dresden e.V., Dresden, Germany.
Susanne BoyeLeibniz-Institut für Polymerforschung Dresden e.V., Dresden, Germany.
Christo TzachevFaculty of Chemistry and Pharmacy, Sofia University "St. Kliment Ohridski", Sofia, Bulgaria.
Jan C SimonDepartment of Dermatology, Venereology and Allergology, Medical Faculty, University of Leipzig, Leipzig, Germany.
Sandra FranzDepartment of Dermatology, Venereology and Allergology, Medical Faculty, University of Leipzig, Leipzig, Germany.
Albena LedererDepartment of Chemistry and Polymer Science, Stellenbosch University, Matieland, South Africa.ORCID 0000-0002-1760-6426

Funding

3D4D2 project carried out under the M-ERA.NET 2 schemeEuropean Union's Horizon 2020 research and innovation programme 685451Saxon State Ministry for Science, Culture and Tourism (Germany) 100579959
6 · The paper itself

Abstract

The development of effective drug delivery systems for subcutaneous or intradermal injection requires systems with improved bioavailability and biocompatibility. Systematic physicochemical and biological interrogation of carnauba-wax/red-palm-oil lipid nanoparticles (LNPs) stabilized with d-α-tocopheryl-PEG-1000-succinate and polysorbate-40 shows that purposeful matrix engineering yields a robust sub-50 nm carrier for under-skin delivery. Cryo-TEM and SAXS reveal hybrid morphology dominated by 30-40 nm toroidal disc-shaped particles. Orthogonal analytics via multidetection asymmetrical flow field-flow fractionation and WAXS confirm that loading with quinine or dihydroartemisinin leaves size and crystallinity unchanged, achieving approximately 90% encapsulation efficiencies and particle stability up to 18 months at 4°C. Formulations containing red palm oil and the dual-surfactant corona exhibited reduced size dispersity compared with single-component formulations. Long-term viability assays in primary human fibroblasts and macrophages, and ex vivo cultured human skin, underscore excellent biocompatibility up to 0.024% (w/v) lipid. Fluorescein-labeled LNPs traversed the dermis and hypodermis, while only nanomolar lipid concentrations appeared in the receiver medium, indicating a sustained local depot. Overall, this study provides insights into the relationship between formulation composition, particle morphology and measured physicochemical and biological properties relevant to under-skin administration.

Indexed as

Drug CompoundingDrug Delivery SystemsLipidsNanoparticlesFibroblastsHumansLiposomesParticle SizeLipid NanoparticlesLipidsLiposomesAF4asymmetrical flow field flow fractionationdisc‐toroid hybriddrug deliverylipid nanoparticlesmultidetectionSAXS

Identifiers

PMID41815035
PMCPMC13155039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.